News
Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...
The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.
The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...
CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...
Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...
The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.
3d
Zacks Investment Research on MSNModerna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspikeModerna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...
Despite uncertainties arising from new FDA policies around COVID-19 vaccines, Moderna has cleared the agency's desk with its ...
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...
1d
Global News - Inquirer.net on MSNCOVID jabs safe despite US alertA vaccine expert assured Filipinos on Wednesday that all vaccines are safe after the United States Food and Drug ...
Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the pharmaceutical company expands its ...
FDA approves Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk groups Phase 3 trial shows mNEXSPIKE outperforms original ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results